On January 14, 2020 LIDDS AB (publ) reported that the United States Patent and Trademark Office has registered the trademark NanoZolid (Press release, Lidds, JAN 14, 2020, View Source [SID1234555898]). LIDDS thereby has exclusive rights to the trademark for products and services in the USA and in the EU, where NanoZolid has been registered since 2016.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The registered Trademark NanoZolid, without any claim to particular font, size or color, has registration no. 5,830,505 and includes International Classes 5 and 42.

-This is an essential, although expected, step in establishing the concept of LIDDS proprietary drug delivery technology NanoZolid for local depots and adds to our already strong IP portfolio, confirms LIDDS CEO Monica Wallter.